Vesicular glutamate transporter (VGLUT) (VGLUT)

Vesicular glutamate transporters (VGLUTs) are essential membrane proteins that mediate the uptake of glutamate, the primary excitatory neurotransmitter in the mammalian central nervous system, into synaptic vesicles (UniProt Q9P2U7, Q9P2U8). This family consists of three isoforms—VGLUT1, VGLUT2, and VGLUT3—which are encoded by the SLC17A7, SLC17A6, and SLC17A8 genes, respectively (PMID: 21496452). These transporters utilize the chemical and electrical components of a proton gradient established by the vacuolar H+-ATPase to drive glutamate transport. VGLUT1 and VGLUT2 are predominantly expressed in distinct glutamatergic pathways, where they serve as definitive markers for excitatory neurons, while VGLUT3 is found in various non-glutamatergic cell types where it may modulate other neurotransmitter systems (PMID: 15140637). The activity of VGLUTs is a critical determinant of the amount of glutamate released per vesicle, thereby directly influencing the strength and plasticity of excitatory synapses. Dysregulation of VGLUT expression or function has been linked to a wide range of neurological and psychiatric conditions, including epilepsy, schizophrenia, and neurodegenerative diseases like Alzheimer's and Parkinson's (PMID: 29936436). While they represent promising therapeutic targets for modulating excitatory tone, current pharmacological agents like Chicago Sky Blue 6B are largely limited to research tools, and clinical applications remain an area of active investigation (PMID: 24652936). Therapeutic development is complicated by the essential nature of these transporters, as VGLUT2 deficiency is neonatally lethal in animal models (PMID: 15548654). Future drug discovery efforts focus on isoform-specific modulation to minimize systemic toxicity and target specific brain regions.

Other names

SLC17A7SLC17A6SLC17A8VGLUT1VGLUT2VGLUT3Solute carrier family 17 member 7Solute carrier family 17 member 6Solute carrier family 17 member 8

VGLUTs act as secondary active transporters that utilize the proton electrochemical gradient (ΔμH+) generated by the vacuolar H+-ATPase to sequester glutamate into synaptic vesicles. Most pharmacological inhibitors act by competing with glutamate for the substrate-binding site or by modulating the chloride-dependent activation of the transporter (PMID: 21496452).